| 中文名称: | 呋喃脒 | ||||
|---|---|---|---|---|---|
| 英文名称: | Furamidine | ||||
| 别名: | DB75; NSC 305831 | ||||
| CAS No: | 73819-26-8 | 分子式: | C18H16N4O | 分子量: | 304.35 |
| CAS No: | 73819-26-8 | ||||
| 分子式: | C18H16N4O | ||||
| 分子量: | 304.35 | ||||
基本信息
|
产品编号：F10238 |
|||||
|
产品名称：Furamidine |
|||||
|
CAS: |
73819-26-8 |
储存条件 |
粉末 |
2-8℃ |
四年 |
|
分子式： |
溶于液体 |
-80℃ |
一年 |
||
|
分子量： |
304.35 |
|
|
||
|
化学名： |
|
||||
|
Solubility (25°C) |
体外 |
DMSO |
|
||
|
Ethanol |
|
||||
|
Water |
|
||||
|
体内（现配现用） |
|
|
|||
|
＜1mg/ml表示微溶或不溶。 |
|||||
|
普西唐提供的所有化合物浓度为内部测试所得，实际溶液度可能与公布值有所偏差，属于正常的批间细微差异现象。 |
|||||
|
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；⼀旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 |
|||||
生物活性
|
产品描述 |
一种选择性的且细胞可渗透的蛋白精氨酸甲基转移酶 1 (PRMT1) 抑制剂，IC50 为 9.4μM。 |
|
|
靶点/IC50 |
9.4μM (Protein arginine methyltransferase 1 (PRMT1));166µM (PRMT5),283µM (PRMT6) and >400µM (PRMT4) |
|
|
体外研究 |
Furamidine (compound 1;20μM;72 hours;leukemia cell lines) inhibits cell growth for most of the leukemia cell lines except HEL cells which have JAK2V617F mutations.Furamidine (compound 1;20μM;15 hours;293T cells) treatment significantly reduces the expression level of the methylated GFP-ALY protein in 293T cells.Furamidine binds duplex DNA in the DNA minor groove selectively at AT rich sites [(A/T)4]. Furamidine can also intercalate between GC base pairs of duplex DNA.Furamidine could therefore interfere with DNA processing enzymes such as TDP-1. Cell Viability Assay |
|
|
Cell Line: |
Meg-01,K562,HL-60,NB4,MOLM13,HEL,CMK,CMY,CMS and CHRF cells |
|
|
Concentration: |
20μM |
|
|
Incubation Time: |
72 hours |
|
|
Result: |
Inhibited cell growth for most of the leukemia cell lines except HEL cells which have JAK2V617F mutations. |
|
|
Western Blot Analysis |
||
|
Cell Line: |
293T cells |
|
|
Concentration: |
20μM |
|
|
Incubation Time: |
15 hours |
|
|
Result: |
The expression level of the methylated GFP-ALY protein is significantly reduced. |
|
|
体内研究 |
Furamidine (1mg/kg;intraperitoneal injection;3 times a week and repeated every 4 weeks;for 34 weeks;female NZB/NZW mice) and Irinotecan combined treatment suppresses proteinuria and prolongs survival of lupus-prone NZB/NZW mice.The combination treatment does not change the levels of anti-dsDNA antibodies. |
|
|
Animal Model: |
Female NZB/NZW mice (6-week-old) with Irinotecan (1 mg/kg) |
|
|
Dosage: |
1mg/kg |
|
|
Administration: |
Intraperitoneal injection;3 times a week and repeated every 4 weeks;for 34 weeks |
|
|
Result: |
Suppressed proteinuria and prolongs survival of lupus-prone NZB/NZW mice combined with Irinotecan. |
|
本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为：
质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)
摩尔浓度计算公式
用本工具协助配置特定浓度的溶液，使用的计算公式为：
开始浓度 x 开始体积 = 最终浓度 x 最终体积
稀释公式
稀释公式一般简略地表示为：C1V1 = C2V2 ( 输入 输出 )
